Brinker International (EAT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors of ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 3 ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Laser Photonics Corporation (“Laser Photonics” or the “Company”) (NASDAQ: LASE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Laser Photonics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the c ...

Las Vegas, NV, June 06, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE:  The Las Vegas Global Economic Alliance (LVGEA) is proud to announce the addition of three distinguished leaders to the LVGEA Board of Directors—Jackie Van Blaricum of HCA Healthcare, Marc Badain of MLB Athletics, and Dr. Chris Heavey of UNLV Leadership. Representing vital sectors of the community, these new members strengthen the board’s ability to shape and support Southern Nevada’s long-term economic growth.  “We’re absolutely thrill ...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 85,000 new shares have been issued on 6 June 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 504,303,905.59. The total number of shares with voting rights after the issue amounts to 73,313,904 which ...

Grupo Aeroportuario del Centro Norte (NASDAQ: OMAB ) is a company that no longer needs to prove anything: it manages 13 airports in Mexico –including the one in Monterrey, one of the most important outside the capital, and is strategically located in theI am an individual investor with over five years of experience in personal investing, holding a PhD in Economics from UCEMA. My investment approach focuses on value companies with solid long-term potential. I share my knowledge with the community by offering ...

Core Insights - Kura Oncology's shares have increased by 15.5% over the past week, contrasting with a 0.1% decline in the industry [1] - The FDA has accepted Kura's new drug application (NDA) for ziftomenib, aimed at treating adult patients with relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation [1][9] - A decision from the FDA regarding the NDA is anticipated on November 30, 2025, following a priority review [1] Company Developments - Ziftomenib is positioned to be the first menin inhibitor approved for treating R/R NPM1-mutant AML if the FDA grants approval [2] - The NDA submission was based on the phase II KOMET-001 study, which achieved its primary endpoint of complete remission and demonstrated statistically significant results [7] - Kura has entered into a partnership with Kyowa Kirin for the development and commercialization of ziftomenib, which triggered a $45 million milestone payment upon NDA submission [6][9] Clinical Pipeline - Ziftomenib is also being explored in combination with imatinib for advanced gastrointestinal stromal tumors after imatinib failure [10] - Kura is developing KO-2806, a next-generation farnesyl transferase inhibitor, for various solid tumors, and another FTI, tipifarnib, in combination with alpelisib for head and neck squamous cell carcinoma [11] - Data from these studies are expected to be presented later in 2025, which may further influence Kura's stock performance [12]

Core Points - Heidmar Maritime Holdings Corp. will release its first quarter results for the period ending March 31, 2025, after market closes on June 10, 2025 [1] - A conference call to discuss the financial results will take place on June 11, 2025, at 8:00 A.M. Eastern Time [1] Conference Call Details - Participants should dial in 10 minutes before the scheduled time using specific toll-free numbers [2] - An alternative "call me" option is available for faster connection to the conference call [3] Webcast Information - A live and archived webcast of the conference call will be available on the Company's website, along with accompanying slides [4] Company Overview - Heidmar is celebrating its 40th anniversary and operates in the crude and product tanker market, focusing on safety, performance, and transparency [5] - The Company has operations in multiple global locations, including Athens, London, Singapore, Chennai, Hong Kong, and Dubai [5] - Heidmar aims to provide a comprehensive solution for vessel owners in the maritime services sector [5]

Company Overview - Guaranty Bancshares Inc. (GNTY) is headquartered in Addison and operates in the Finance sector [3] - The stock has experienced a price change of 17.43% since the beginning of the year [3] - The company currently pays a dividend of $0.25 per share, resulting in a dividend yield of 2.46%, which is higher than the Banks - Southwest industry's yield of 1.27% and the S&P 500's yield of 1.56% [3] Dividend Performance - The current annualized dividend of $1 represents a 4.2% increase from the previous year [4] - Over the past 5 years, Guaranty Bancshares has increased its dividend 5 times, achieving an average annual increase of 7.12% [4] - The company's current payout ratio is 34%, indicating that it paid out 34% of its trailing 12-month earnings per share as dividends [4] Earnings Growth - Earnings growth for GNTY appears solid, with the Zacks Consensus Estimate for 2025 projected at $3.30 per share, reflecting a year-over-year growth rate of 20.44% [5] Investment Appeal - GNTY is considered a compelling investment opportunity due to its attractive dividend and strong Zacks Rank of 1 (Strong Buy) [7] - The company is positioned as a better dividend option compared to high-growth firms or tech start-ups, which typically do not provide dividends [7]